Search

Search bills, members, committees and pages...

S. 832

U.S. SenateIn Senate Committee

Summary

S. 832, the EPIC Act of 2025, was introduced in the Senate on Mar 4, 2025 by Sen. Thom Tillis (R) with 7 co-sponsors. It was referred to Finance, and last saw action on Mar 4, 2025: Read twice and referred to the Committee on Finance.


Record

Text

S. 832 has 7 co-sponsors.

sb832/introduced-in-senate.txt
119 S832 IS: Ensuring Pathways to Innovative Cures Act of 2025
U.S. Senate
2025-03-04
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
II 119th CONGRESS 1st Session S. 832 IN THE SENATE OF THE UNITED STATES March 4, 2025 Mr. Tillis (for himself, Mr. Budd , Mrs. Blackburn , Mr. Daines , and Mr. Lankford ) introduced the following bill; which was read twice and referred to the Committee on Finance A BILL
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
1.
Short title
This Act may be cited as the Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 .
2.
Equalizing the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program
Section 1192(e)(1)(A)(ii) of the Social Security Act ( 42 U.S.C. 1320f–1(e)(1)(A)(ii) ) is amended—
(1)
by striking year, at least 7 and inserting “year—
(I)
for initial price applicability years 2026 and 2027, at least 7
; and
(2)
by adding at the end the following:
(II)
for initial price applicability year 2028 and each subsequent initial price applicability year, at least 11 years will have elapsed since the date of such approval; and
.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2025-03-04
  2. Passed Senate
  3. Passed House
  4. Conference
  5. To President
  6. Became Law

CRS Summary

The summaries are the Congressional Research Service’s, one per stage. Read them in full.

Introduced in Senate Mar 4, 2025

sb832/introduced-in-senate.md

Shown Here:
Introduced in Senate (03/04/2025)

Sponsors

Sen. Thom Tillis (R) sponsors S. 832, and 7 members have co-sponsored it, 4 of them from the day it was introduced.

Committees

S. 832 went before 1 committee: Finance.

Finance
Finance
Referred To · Mar 4, 2025 · 902 Bills

Actions

S. 832 has taken 2 actions since Mar 4, 2025.

ChamberAction
Mar 4, 2025
Senate
Read twice and referred to the Committee on Finance.Finance Committee
Mar 4, 2025
Introduced in Senate

Votes

S. 832 has not gone to a roll call.

Titles

S. 832 goes by 4 titles, 2 of them short titles.

  • EPIC Act of 2025 — Display Title
  • EPIC Act of 2025 — Short Title(s) as Introduced
  • Ensuring Pathways to Innovative Cures Act of 2025 — Short Title(s) as Introduced
  • A bill to amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. — Official Title as Introduced

Lobbying

34 clients hired 40 firms and 248 registered lobbyists who named S. 832 in 196 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Health Issues, Medicare/Medicaid, Trade (domestic/foreign), Budget/Appropriations, Taxation/Internal Revenue Code, Copyright/Patent/Trademark, Pharmacy, Labor Issues/Antitrust/Workplace.

Clients

Who paid to be heard, by how many filings named the bill. The 20 that filed most often, of 34.

ClientBusinessStateFirmsFilingsReported
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICATrade association of innovative biopharmaceutical research companies.District of Columbia525$940K
NOVARTISInnovative medicines company.District of Columbia213$280K
PHRMARepresents country's leading pharmaceutical research and biotechnology companiesDistrict of Columbia311$630K
NOVARTIS, INC.Multinational biopharmaceutical companyDistrict of Columbia29$500K
JOB CREATORS NETWORKadvocacy organization for small businessTexas19$55.5K
BAYER CORPORATION (CONSOLIDATED REPORT)District of Columbia19
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)trade group representing U.S. pharmaceutical research and biotechnology companiesDistrict of Columbia28$290K
BOEHRINGER INGELHEIM USA CORPORATIONLobbyistsDistrict of Columbia18
SOLENO THERAPEUTICS, INC.Soleno is focused on development of novel therapeutics for treatment of rare diseases.California27$170K
GSK (FKA GLAXOSMITHKLINE INC.)District of Columbia17
LUNDBECK LLCDistrict of Columbia17
PUBLIC CITIZENDistrict of Columbia17
TAKEDA PHARMACEUTICALS AMERICA INCDistrict of Columbia17
EMD SERONO INCDistrict of Columbia16
HEALTHCARE INSTITUTE OF NEW JERSEYNew Jersey16
JOHNSON & JOHNSON SERVICES INCNew Jersey16
NEUROCRINE BIOSCIENCES, INCCalifornia16
CONSERVATIVES FOR PROPERTY RIGHTSCoalitionSouth Carolina15$188K
BIOGENDistrict of Columbia15
PERSONALIZED MEDICINE COALITIONHealth careDistrict of Columbia15

Firms

Registrants who filed on the bill, by filings.

Lobbyists

Named on the filings that cite the bill. The 20 named most often, of 248.

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

ClientRegistrantPeriodReportedDocument
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2025 first_quarter$12.9M1st Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2026 first_quarter$12.2M1st Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2025 third_quarter$9M3rd Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2025 fourth_quarter$8.4M4th Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2025 second_quarter$7.6M2nd Quarter - Report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA2026 second_quarter$7.4M2nd Quarter - Report
AARPAARP2025 fourth_quarter$5.3M4th Quarter - Report
AARPAARP2025 second_quarter$5.1M2nd Quarter - Report
NOVARTISNOVARTIS2025 first_quarter$4.2M1st Quarter - Report
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATIONPHARMACEUTICAL CARE MANAGEMENT ASSOCIATION2025 first_quarter$4.1M1st Quarter - Report
NOVARTISNOVARTIS2026 first_quarter$3.9M1st Quarter - Report
AARPAARP2025 third_quarter$3.8M3rd Quarter - Report
JOHNSON & JOHNSON SERVICES INCJOHNSON & JOHNSON SERVICES, INC.2026 first_quarter$3.5M1st Quarter - Report
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATIONPHARMACEUTICAL CARE MANAGEMENT ASSOCIATION2025 second_quarter$3.4M2nd Quarter - Report
JOHNSON & JOHNSON SERVICES INCJOHNSON & JOHNSON SERVICES, INC.2025 first_quarter$3.3M1st Quarter - Report
BAYER CORPORATION (CONSOLIDATED REPORT)BAYER CORPORATION (CONSOLIDATED REPORT)2025 first_quarter$3M1st Quarter - Report
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATIONPHARMACEUTICAL CARE MANAGEMENT ASSOCIATION2025 third_quarter$2.9M3rd Quarter - Report
SANOFI US SERVICES INCSANOFI US SERVICES INC.2026 first_quarter$2.6M1st Quarter - Report
SANOFI US SERVICES INCSANOFI US SERVICES INC.2025 first_quarter$2.5M1st Quarter - Report
BAYER CORPORATION (CONSOLIDATED REPORT)BAYER CORPORATION (CONSOLIDATED REPORT)2025 second_quarter$2.5M2nd Quarter - Report

Classification

The Congressional Research Service files S. 832 under Health, one of its 31 policy areas.

CRS Subjects

CRS assigns every bill one policy area from its 31; S. 832’s is Health.

s832/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Source: congress.gov · legiscan.com